10-K/A: DT Cloud Acquisition Corporation Amends Annual Report, Details SPAC Business Combination Progress and Leadership Changes Amidst Redemptions

DT Cloud Acquisition Corporation filed an amendment to its annual report, providing updated information on its proposed business combination with Maius Pharmaceutical, extensions to its acquisition deadline, and changes in executive leadership.

Summary

• DT Cloud Acquisition Corporation (the 'Company'), a blank check company, filed an amendment (Form 10-K/A) to its annual report for the fiscal year ended December 31, 2024, primarily updating information on Directors, Executive Officers, Corporate Governance, and Exhibits.
• The Company consummated its initial public offering (IPO) on February 23, 2024, raising $69,000,000 gross proceeds from 6,900,000 units at $10.00 per unit, and a simultaneous private placement of 234,500 units for $2,345,000.
• A total of $69,345,000 from the IPO and private placement was deposited into a trust account for the benefit of public shareholders.
• On October 22, 2024, the Company entered into a definitive business combination agreement with Maius Pharmaceutical Co., Ltd. and Maius Pharmaceutical Group Co., Ltd. ('Pubco'), with an aggregate consideration of $250,000,000 to be paid in newly issued Pubco ordinary shares.
• The deadline for completing the business combination was automatically extended by three months to February 23, 2025, upon signing the Business Combination Agreement.
• Further extensions were secured through Sponsor deposits: $207,000 on February 22, 2025, extending the deadline to March 23, 2025, and $150,949 on March 25, 2025, extending it to April 23, 2025.
• Shareholders approved an amendment on March 20, 2025, allowing for extensions up to 27 months from the IPO closing (May 23, 2026), contingent on Sponsor deposits.
• In connection with the March 20, 2025, extraordinary general meeting, 1,868,367 ordinary shares were redeemed for approximately $10.61 per share, totaling $19,821,345.
• Following these redemptions, 5,031,633 ordinary shares remain issued and outstanding subject to redemption.
• As of December 31, 2024, the Company reported a net income of $2,265,806, primarily driven by $3,000,071 in dividend income from the trust account, offset by $734,291 in formation and operating costs.
• The Company had $152,021 in cash and a working capital deficit of $128,968 as of December 31, 2024.
• The Sponsor and initial shareholders collectively own 27.6% of the Company's issued and outstanding ordinary shares and have agreed to vote in favor of the business combination and waive redemption rights for their shares.
• The Company identified a material weakness in its internal control over financial reporting due to a lack of segregation of duties and insufficient written policies and procedures.
• Guojian Chen is now listed as Chief Executive Officer, Chief Financial Officer, and Director, indicating a change from the previous CEO, Shaoke Li, who is no longer listed in the executive officer and director section.

Sentiment

Score: 3

Explanation: While a definitive business combination agreement is in place and extensions are being secured, the significant redemptions, unfulfilled PIPE financing target, and the 'going concern' warning indicate substantial financial challenges and uncertainty. The internal control weaknesses and potential conflicts of interest further contribute to a negative outlook, outweighing the positive step of securing a target.

Positives

• The Company has successfully entered into a definitive business combination agreement with Maius Pharmaceutical Co., Ltd., providing a clear path forward for its SPAC objective.
• The Sponsor and shareholders have demonstrated commitment to the business combination by approving and funding multiple extensions to the acquisition deadline, extending it to April 23, 2025, with potential for further extensions until May 23, 2026.
• The Company reported a net income of $2,265,806 for the year ended December 31, 2024, primarily from interest earned on funds held in the trust account.
• The management team is highlighted for its deep experience in deal-making, investment, and access to proprietary sourcing channels and industry relationships, which are expected to aid in identifying and structuring attractive transactions.

Negatives

• Significant redemptions occurred in March 2025, with 1,868,367 ordinary shares redeemed for $19,821,345, substantially reducing the cash available for the business combination.
• The target PIPE financing of at least $10,000,000 has not been fully secured, with only $300,000 committed as of January 20, 2025, creating uncertainty regarding the funding of the business combination.
• The Company had a working capital deficit of $128,968 as of December 31, 2024, indicating potential liquidity challenges outside the trust account.
• The auditor's report includes an explanatory paragraph expressing 'substantial doubt about our ability to continue as a going concern' if the business combination is not consummated within the prescribed period.
• Management identified a material weakness in internal control over financial reporting due to limited personnel and insufficient written policies and procedures.

Risks

• Inability to consummate a business combination within the required timeframe (currently April 23, 2025, with potential extensions to May 23, 2026) could lead to liquidation, resulting in public shareholders receiving less than their initial investment and rights expiring worthless.
• Potential target businesses may gain leverage in negotiations due to the Company's time constraints to complete a business combination.
• Conflicts of interest exist for the Sponsor, directors, and officers, as their founder shares and private units would become worthless if a business combination is not completed, potentially incentivizing them to pursue riskier targets.
• There is no assurance that the Business Combination with Maius Pharmaceutical will be completed on the terms or timeline currently contemplated, or at all, due to various closing conditions and regulatory approvals.
• Uncertainty regarding the completion of the $10,000,000 PIPE financing could make the business combination less attractive to investors and lead to further dilution for non-redeeming shareholders.
• The Business Combination may be a taxable event for U.S. Holders of the Company's ordinary shares and rights.
• Insufficient funds to consummate the Business Combination or fund the target business's operations and growth if additional financing is not secured.
• Proceeds held in the trust account could be reduced by third-party claims if waivers are not legally enforceable or obtained, potentially leading to a per-share redemption price less than $10.05.
• Shareholders may be held liable for claims by third parties to the extent of distributions received if the Company enters an insolvent liquidation.
• Deviation from stated acquisition criteria or guidelines could lead to rescission rights for shareholders or legal actions against the Company.
• The Company's success is highly dependent on its key personnel, and their assessment of individuals joining post-business combination may not be correct.
• Officers and directors may lack significant experience or knowledge regarding the jurisdiction or industry of the target business (e.g., Maius in China), potentially leading to suboptimal decisions.
• Conflicts of interest may arise from key personnel negotiating employment or consulting agreements with the target business, influencing their motivation.
• Officers and directors allocate time to other businesses, potentially limiting their dedication to the Company's affairs.
• Pre-existing fiduciary and contractual obligations of officers and directors may lead to conflicts in presenting business opportunities.
• Nasdaq may delist the Company's securities from trading, limiting liquidity and subjecting the Company to additional trading restrictions, especially if initial listing requirements are not met post-business combination or due to HFCAA.
• Acquiring and operating a business outside the United States, particularly in China, subjects the Company to additional risks including regulatory changes, currency fluctuations, political instability, and difficulties in enforcing legal rights.
• The PRC government's evolving policies on business operations, overseas issuance, and foreign investment in China-based issuers could materially change the target company's operations and/or the value of securities.
• U.S. laws like the HFCAA may restrict or eliminate the ability to complete a business combination with certain companies, particularly those with substantial operations in mainland China or Hong Kong, due to audit inspection issues.
• Compliance with PRC Antitrust law may limit or delay the ability to effect the initial business combination.
• The nominal purchase price paid by initial shareholders for founder shares may significantly dilute the implied value of public shares upon business combination.
• Issuance of additional ordinary or debt securities to complete a business combination could reduce the equity interest of existing shareholders and potentially cause a change in control.
• Holders of rights will not have redemption rights if the business combination is not completed and the Company liquidates, and the Company has no obligation to net cash settle the rights, which may expire worthless.
• Public shareholders may not have an opportunity to vote on the proposed business combination if the Company opts for a tender offer.
• The ability of a large number of shareholders to exercise redemption rights may prevent the Company from effectuating the most desirable business combination or optimizing its capital structure.
• Limited funds held outside the trust account may be insufficient to cover operating expenses and search costs, potentially forcing liquidation if additional financing is not secured.
• The Company may be required to take write-downs, write-offs, restructuring, or impairment charges post-business combination due to unforeseen issues or external factors.
• Directors may choose not to enforce indemnification obligations against the Sponsor, potentially reducing funds available for public shareholders in the trust account.
• Conversion of promissory notes into private units may adversely affect the market price of ordinary shares and complicate the business combination.
• Shareholders exercising registration rights could adversely affect the market price of ordinary shares.
• Risk of being deemed an investment company under the Investment Company Act, which would severely restrict activities and could lead to liquidation.
• The Company is not required to obtain an independent third-party opinion on the fair market value of the target business unless the board cannot determine it or the target is affiliated.
• The Company may acquire a target business affiliated with its officers, directors, or initial shareholders, raising potential conflicts of interest.
• A market for the Company's securities may not develop, adversely affecting liquidity and price.
• Resources could be wasted on researching acquisitions that are not consummated.
• Difficulty evaluating private target companies due to limited publicly available information.
• Inability to maintain control of a target business after the initial business combination.
• Dependence on U.S. and multi-national financial institutions for banking services exposes the Company to risks of financial institution default or failure.
• Difficulties in protecting interests and enforcing rights for investors due to the Company's Cayman Islands incorporation and officers/directors residing outside the U.S.
• The Company is exempt from certain blank check company protections (Rule 419), meaning units are immediately tradable and funds can be withdrawn from the trust account prior to business combination completion.
• Reduced disclosure requirements as an emerging growth company and smaller reporting company may make the Company's securities less attractive to investors.
• Compliance with the Sarbanes-Oxley Act requires substantial financial and management resources and may increase acquisition costs.
• Cyber incidents or attacks could result in information theft, data corruption, operational disruption, and/or financial loss.

Future Outlook

The Company intends to complete its business combination with Maius Pharmaceutical Co., Ltd., leveraging its management team's expertise to identify and acquire a target with competitive advantages, high returns, and long-term sustainable growth. The Sponsor currently intends to continue extending the business combination deadline up to 27 months from the IPO closing (May 23, 2026) by depositing additional funds into the Trust Account, though there is no guarantee these deposits will be made timely or at all. The Company and Maius are using commercially reasonable efforts to secure an aggregate PIPE investment of no less than $10,000,000, but substantial uncertainties remain regarding the financing amount, terms, and timing.

Management Comments

• "Nevertheless, we are confident that we will be able to find a target business that will meet expectations."
• "Our Sponsor currently intends to continue to deposit additional funds as described herein to further extend such deadline to up to 27 months from the closing of the IPO, to complete the initial business combination. However, there is no guarantee that our sponsor will make such deposit timely or at all as described above."
• "Our management has determined that we have funds that are sufficient to fund the working capital needs of us until the consummation of an initial business combination or the winding up of our company as stipulated in the amended and restated memorandum and articles of association."
• "Our management will promptly report to the board of directors on incidents of material cybersecurity risks facing us and any third parties and the measures that may be taken to mitigate such risks."

Industry Context

The document reflects the current competitive landscape for Special Purpose Acquisition Companies (SPACs), noting an increase in their formation and the resulting heightened competition for attractive target businesses. This competition can lead to increased acquisition costs and difficulty in finding suitable targets. The filing also highlights the complex regulatory environment for foreign investments, particularly in China, which is relevant given the potential target (Maius Pharmaceutical) and the Sponsor's ties to Macau and the PRC. This includes evolving policies on data security, cybersecurity reviews, and the Holding Foreign Companies Accountable Act (HFCAA), which could impact the feasibility and value of cross-border business combinations. The general volatility in global markets and geopolitical tensions are also cited as factors that could adversely affect the Company's ability to find and consummate a business combination.

Management Changes

Corporate Governance

Related Party Transactions

• In August 2022, 1,725,000 insider shares were issued to initial shareholders for an aggregate purchase price of $25,000 (approximately $0.01 per share).
• On February 23, 2024, the Company consummated a private placement with DT Cloud Capital Corp. (the Sponsor) of 234,500 units at $10.00 per unit, generating $2,345,000.
• An unsecured promissory note was issued to the Sponsor on August 5, 2022, allowing the Company to borrow up to $300,000 (non-interest-bearing, convertible into private units upon business combination). As of December 31, 2024, the principal amount due was $0.
• Temporary advances from the Sponsor amounted to $129,759 as of December 31, 2024, which are unsecured, interest-free, and have no fixed repayment terms.
• The Company pays an affiliate of the Sponsor $10,000 per month for office space, utilities, secretarial, and administrative support services, commencing from the Nasdaq listing date. $100,000 was incurred for these services in 2024.
• The Sponsor, officers, directors, or their affiliates may provide working capital loans (up to $300,000 convertible into private units) to finance transaction costs in connection with a business combination. No principal amount was due as of December 31, 2024.
• Registration rights were granted to holders of insider shares, private placement units, and units that may be issued upon conversion of working capital or extension loans, requiring the Company to register such securities for resale.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares for the business combination and conversion of rights or promissory notes. They also bear the risk of losing their investment if the business combination fails and the Company liquidates.
• Public shareholders who redeemed their shares in March 2025 received approximately $10.61 per share, but those who remain face uncertainty due to the unfulfilled PIPE financing and the 'going concern' warning.
• The Sponsor and initial shareholders have a significant financial incentive to complete the business combination, as their founder shares would become worthless otherwise. They are also responsible for funding extensions to the business combination deadline.
• Employees (post-business combination) may experience changes in management structure, as the target business's management is likely to remain, potentially supplemented by new recruits.
• Creditors' claims may take priority over public shareholders in the event of liquidation, although the Sponsor has agreed to be liable for certain debts to protect the trust account.
• The target business, Maius Pharmaceutical, stands to benefit from becoming a publicly traded company through the SPAC merger, gaining broader access to capital and an enhanced public profile.
• Regulatory bodies, particularly in the U.S. and China, will continue to oversee the Company's activities, especially regarding foreign investment, data security, and audit compliance, which could impact the business combination.

Next Steps

• Complete the business combination with Maius Pharmaceutical Co., Ltd. and Maius Pharmaceutical Group Co., Ltd. (Pubco).
• Continue efforts to secure the remaining PIPE financing to meet the aggregate investment target of at least $10,000,000.
• Maius Pharmaceutical is expected to fulfill filing procedures with the CSRC and report relevant information in a timely manner.
• Obtain approval for Pubco's initial listing application with Nasdaq.
• The Sponsor intends to continue depositing additional funds into the Trust Account to further extend the business combination deadline up to May 23, 2026, if necessary.
• The Company's management will continue to expend effort and resources for the remediation and improvement of its internal control over financial reporting.

Key Dates

Recommendation

Keywords

SPAC, Business Combination, Maius Pharmaceutical, SEC Filing, 10-K/A, Corporate Governance, Risk Factors, Financial Reporting, Trust Account, Redemption, PIPE Investment, Nasdaq, Cayman Islands, China, Pharmaceutical, Blank Check Company, Executive Compensation, Internal Controls